Ces Urol 2020, 24(3):173-182 | DOI: 10.48095/cccu2020012

The role of urologist in the treatment of multiple sclerosis complication

Gabriel Varga
Urologická klinika FN Brno, Brno
Lékařská fakulta MU Brno, Brno

Major statement: The aim of this review is to recapitulate the treatment of urological problems associated with multiple sclerosis. In particular, the article discusses the current treatment options for lower urinary tract dysfunction, which represent a dominant problem in this patient population. The article also deals with urinary tract infections and sexual dysfunction. Varga G. The role of urologist in the treatment of multiple sclerosis complication. The review recapitulates the current treatment of urological problems associated with multiple sclerosis. The article is focused on the treatment of lower urinary tract dysfunction as the dominant symptomatology in this patient population. However, it also marginally mentions treatment options for urinary tract infections and sexual dysfunction, which are often overlooked by the professional community.

Keywords: Multiple sclerosis, neurogenic dysfunction of the lower urinary tract, uroinfection, sexual dysfunction.

Received: January 6, 2020; Accepted: April 16, 2020; Prepublished online: April 23, 2020; Published: October 2, 2020 

Open full article

References

  1. Havrdová E. Roztroušená skleróza. Praha: Maxdorf 2005; 11.
  2. Landtblom AM, Fazio P, Fredrikson S, Granieri E. The first case history of multiple sclerosis: Augustus d´Este (1794-1848). Neurol Sci 2010; 31(1): 29-33. Go to original source... Go to PubMed...
  3. Koldewijn EL, Hommes OR, Lemmens WA, et al. Relationship between lower urinary tract abnormalities and disease‑related parameters in multiple sclerosis. J Urol. 1995; 154(1): 169-173. Go to original source...
  4. Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 1999; 161(3): 743-757. Go to original source...
  5. Zachoval R. Mikční dysfunkce u pacientů s roztroušenou sklerózou. In: Krhut J, editor. Neurourologie. Praha: Nakladatelství Galén 2005; 11: 77-83.
  6. Khan F, Pallant JF, Shea TL, et al. Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil 2009; 31(19): 1567-1576. Go to original source... Go to PubMed...
  7. de Seze M, Ruffion A, Denys P, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13(7): 915-928. Go to original source... Go to PubMed...
  8. Wyndaele JJ, Kovindha A, Madersbacher H, et al. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, 4th Edition. Plymouth: Health Publication Ltd. 2009: 793-960.
  9. Krhut J, Zapletalová O, Zachoval R, et al. Doporučení pro diagnostiku a léčbu symptomů dolních močových cest u pacientů s roztroušenou sklerózou v České republice - mezioborový mezioborový konsenzus expertů dle metodiky DELPHI. Cesk Slov Neurol N 2017; 80/-113(2): 233-237. Go to original source...
  10. Blok B, Castro‑Diaz D, Del Popolo G, et al. Neuro‑urology. Arnhem, The Netherlands: EAU Guidelines Office; 2019.
  11. McClurg D, Ashe RG, Marshall K, Lowe‑Strong AS. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn. 2006; 25(4): 337-348. Go to original source... Go to PubMed...
  12. Lucio AC, Campos RM, Perissinotto MC, et al. Pelvic floor muscle training in the treatment of lower urinary tract dysfunction in women with multiple sclerosis. Neurourol Urodyn 2010; 29(8): 1410-1413. Go to original source... Go to PubMed...
  13. McClurg D, Ashe RG, Lowe‑Strong AS. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis - a double blind, placebo controlled, randomised clinical trial. Neurourol Urodyn 2008; 27(3): 231-237. Go to original source... Go to PubMed...
  14. Fjorback MV, Van Rey FS, Rijkhoff NJM, et al. Electrical stimulation of sacral dermatomes in multiple sclerosis patients with neurogenic detrusor overactivity. Neurourol Urodyn 2007; 26(4): 525-530. Go to original source... Go to PubMed...
  15. Centonze D, Petta F, Versace V, et al. Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. Mult Scler 2007; 13(2): 269-271. Go to original source... Go to PubMed...
  16. Nasios G, Messinis L, Dardiotis E, Papathanasopoulos P. Repetitive Transcranial Magnetic Stimulation, Cognition, and Multiple Sclerosis: An Overview. Behav Neurol 2018; doi: 10.1155/2018/8584653. Go to original source... Go to PubMed...
  17. De Ridder D, Ost D, Van der Aa F, et al. Conservative bladder management in advanced multiple sclerosis. Mult Scler 2005; 11(6): 694-699. Go to original source... Go to PubMed...
  18. Krhut J, Borovicka V, Bilkova K et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity‑prospective, randomized, double‑blind, placebo‑controlled study. Neurourol Urodyn 2018; 37(7): 2226-2233. Go to original source... Go to PubMed...
  19. Valiquette G, Herbert J, Maede‑D' Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double‑blind, crossover trial. Arch Neurol 1996; 53(12): 1270-1275. Go to original source... Go to PubMed...
  20. Odeh M, Oliven A. Coma and seizures due to severe hyponatremia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis. J Clin Pharmacol 2001; 41(5): 582-584. Go to original source... Go to PubMed...
  21. Abo Youssef N, Schneider MP, Mordasini L, et al. Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta‑analysis. BJU Int 2017; 119(4): 515-521. Go to original source... Go to PubMed...
  22. Francomano D, Ilacqua A, Cortese A, et al. Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study. J Endocrinol Invest 2017; 40(3): 275-279. Go to original source... Go to PubMed...
  23. Schroder A, Albrecht U, Schnitker J, Reitz A, Stein R. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi‑center trial. Neurourol Urodyn 2016; 35(5): 582-588. Go to original source... Go to PubMed...
  24. Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998; 160(3 Pt 1): 892-896. Go to original source...
  25. Cheng T, Shuang W‑b, Jia D‑d, et al. Efficacy and safety of onabotulinumtoxin A in patients with neurogenic detrusor overactivity: A systematic review and meta‑analysis of randomized controlled trials. PLOS ONE 2016; 11(7): e0159307. Go to original source...
  26. De Ridder D, Van Poppel H, Baert L, et al. From time dependent intermittent selfcatheterisation to volume dependent selfcatheterisation in Multiple Sclerosis using the PCI 5000 Bladdermanager(R). Spinal cord 1997; 35: 613-616. Go to original source... Go to PubMed...
  27. Giannantoni A, Scivoletto G, Di Stasi SM, et al. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn 1998; 17(2): 89-98. Go to original source...
  28. Wall BM, Dmochowski RR, Malecha M, et al. Inducible nitric oxide synthase in the bladder of spinal cord injured patients with a chronic indwelling urinary catheter. J Urol 2001; 165(5): 1457-1461. Go to original source...
  29. Ozawa H, Uematsu K, Ohmori H, et al. Long‑term usefulness and safety of the contemporary balloon catheter. Nihon Hinyokika Gakkai Zasshi. 2005; 96(5): 541-547. Go to original source... Go to PubMed...
  30. Chartier‑Kastler EJ, Ruud Bosch JL, Perrigot M, et al. Long‑term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 2000; 164(5): 1476-1480. Go to original source...
  31. Zachoval R, Pitha J, Medova E, et al. Augmentation cystoplasty in patients with multiple sclerosis. Urol Int 2003; 70(1): 21-26. Go to original source... Go to PubMed...
  32. Phé V, Pakzad M, Curtis C, et al. Urinary tract infections in multiple sclerosis. Mult Scler 2016; 22(7): 855-861. Go to original source... Go to PubMed...
  33. Marrie RA, Elliott L, Marriott J, et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology 2014; 83(10): 929-937. Go to original source... Go to PubMed...
  34. Mahadeva A, Tanasescu R, Gran B. Urinary tract infections in multiple sclerosis: under‑diagnosed and under‑treated? A clinical audit at a large University Hospital. Am J Clin Exp Immunol 2014; 3(1): 57-67.
  35. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1(8441): 1313-1315. Go to original source... Go to PubMed...
  36. Winkelmann A, Loebermann M, Reisinger EC, et al. Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol 2014; 175(3): 425-438. Go to original source... Go to PubMed...
  37. Guo ZN, He SY, Zhang HL, et al. Multiple sclerosis and sexual dysfunction. Asian J Androl 2012; 14(4):530-535. Go to original source... Go to PubMed...
  38. Shridharani AN, Brant WO. The treatment of erectile dysfunction in patients with neurogenic disease. Transl Androl Urol 2016; 5(1): 88-101.
  39. Foley FW, LaRocca NG, Sanders AS, Zemon V. Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. Mult Scler 2001; 7(6): 417-421. Go to original source... Go to PubMed...
  40. Fragala E, Russo GI, Di Rosa A, et al. Relationship between urodynamic findings and sexual function in multiple sclerosis patients with lower urinary tract dysfunction. Eur J Neurol 2015; 22(3): 485-492. Go to original source... Go to PubMed...
  41. Lombardi G, Musco S, Wyndaele JJ, et al. Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study. Spinal Cord 2015; 53(12): 849-854. Go to original source... Go to PubMed...
  42. Cardenas DD, Ditunno JF, Graziani V, et al. Two phase 3, multicenter, randomized, placebo‑controlled clinical trials of fampridine‑SR for treatment of spasticity in chronic spinal cord injury. Spinal Cord 2014; 52(1): 70-76. Go to original source... Go to PubMed...
  43. Kessler TM, Fowler CJ, Panicker JN. Sexual dysfunction in multiple sclerosis. Expert Rev Neurother 2009; 9(3): 341-350. Go to original source... Go to PubMed...

Return to the content



Web časopisu Česká urologie je určen pouze pro lékaře a odborníky
z oblasti medicíny nebo farmacie.



Beru na vědomí, že informace zveřejněné na těchto stránkách
nejsou určeny pro laickou veřejnost.


Odejít Vstoupit